The edition · Rheumatology
The cost of a late axSpA diagnosis shows up after ten years
A Swiss registry followed 376 patients for a mean of 11.5 years: those diagnosed within two years of symptom onset had nearly six mSASSS units less spinal damage, and the gap only opened at ten to fifteen years. Plus first-line biologics in early RA, avacopan and severe infection, and what maternal lupus does to the fetal heart.
The edition in brief
Today's rheumatology edition opens with a longitudinal analysis from the Swiss Clinical Quality Management registry. Among 376 patients with axial spondyloarthritis and 1,181 sets of spinal radiographs scored by two readers with adjudication, 138 had been diagnosed within two years of axial symptom onset and 238 later. Over a mean 11.5 years of follow-up, early-diagnosed patients had 3.85 fewer mSASSS units of spinal damage (95% CI -7.28 to -0.42), rising to 5.70 units (-9.31 to -2.09) after adjustment for baseline damage. The difference only became visible ten to fifteen years after diagnosis. A meta-analysis of 29 randomised trials and 13,387 participants with early rheumatoid arthritis found that starting a biologic or targeted synthetic DMARD alongside methotrexate raised DAS28 remission at six months compared with methotrexate alone (risk ratio 1.62, 95% CI 1.39-1.89), sustained at twelve months. As monotherapy the benefit held overall but at class level only for tocilizumab and JAK inhibitors. In a multicentre cohort of 387 patients with ANCA-associated vasculitis, avacopan exposure modelled as time-varying was associated with a lower risk of severe infection (adjusted hazard ratio 0.22, 95% CI 0.07-0.68) and lower cumulative prednisolone, with no significant difference in relapse. And 53 studies covering 33,694 lupus pregnancies put structural cardiovascular malformations at 3.29% and congenital heart block at 1.29%.
First-line biologics in early RA: higher remission, at six months and at twelve
Where cost allows, consider starting a b/tsDMARD with methotrexate in early RA with high disease activity and rheumatoid factor positivity.
Avacopan and severe infection: the steroid-sparing argument, measured
Weigh avacopan's steroid-sparing effect as a plausible infection benefit in ANCA-associated vasculitis, while treating the size of that benefit as unsettled.
Maternal lupus and the fetal heart: the structural risk is the clearer one
Counsel on lupus pregnancy using anti-SSA/Ro status and disease activity rather than the diagnosis alone, and quote the adjusted risk.
FDA approves a supplement to Cibinqo (abrocitinib)
Note the Cibinqo supplement, check whether JAK class labelling moved with it, and do not read it as a new indication.
Ask when the back pain started, not when it got bad
Take the date of first axial symptoms explicitly and write it down, because that clock decides whether the patient is early or established.
Early axSpA diagnosis showed less spinal damage — but only after ten years
Argue for earlier axSpA referral on long-term spinal damage, because the benefit does not appear in the first decade.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free